Responses
Scientific Abstracts
Oral Presentations
Insights into gout management
OP0295 A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS
Compose a Response to This Article
Other responses
No responses have been published for this article.